Trial Profile
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Mitomycin (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms OPTIMA II
- Sponsors UroGen Pharma
- 02 Dec 2022 According to an UroGen Pharma media release, data from this study was presented were presented at the 23rd Annual Society of Urological Oncology (SUO) Meeting.
- 02 Dec 2022 Results (cut off : 25 February 2022) published in an UroGen Pharma media release.
- 31 May 2022 Results of an analysis assessed the patient-reported outcome measure assessing side effects published in the Journal of Urology